DCFBC F-18 is a radioconjugate containing a low molecular weight tracer, DCFBC, specific for prostate-specific membrane antigen (PSMA) and labeled with the positron-emitting isotope fluorine F 18 with potential prostate tumor imaging upon positron emission tomography (PET). Upon administration, the DCFBC moiety of fluorine F 18 DCFBC specifically targets and binds to the tumor-associated antigen PSMA, thereby allowing the visualization of tumor cells expressing PSMA upon PET. F 18 DCFBC is investigated in phase 2 clinical trials in patients with prostate cancer.

Flutriciclamide F18 (18F-GE-180), a translocator protein (TSPO)-PET radiotracer was used using in different pathologies. This agent was studied in phase I clinical trial to assess inflammation in rheumatoid arthritis. However, this study was terminated because of the pre-defined stopping criteria in the protocol.

Fluorfenidine F-18 is a radionucleotide used in positron emission tomography (PET) imaging procedures.

Spiroxamine is a spirodecane derivative patented by German multinational pharmaceutical and life sciences company Bayer A.-G. as agrochemical fungicide. Spiroxamine acts as a sterol biosynthesis inhibitor with systemic activity. This active ingredient provides control of powdery mildew caused by the ascomycetous fungus, Uncinula necator (syn. Erysiphe necator) in grapes. In laboratory animals, the technical grade Spiroxamine was moderate to highly acutely toxic by the oral route and slightly acutely toxic by the dermal and inhalation routes of exposure. Spiroxamine was non-irritating to the eyes but moderately irritating to the skin. Spiroxamine caused an allergic skin reaction. Health effects in animals given repeated doses of Spiroxamine included effects on the liver, lining of the gastrointestinal and urogenital tracts, the eye and body weight. Spiroxamine did not cause cancer in animals and did not damage genetic material.

Amcasertib is an orally administered investigational agent designed to inhibit cancer stemness pathways, including Nanog, by targeting stemness kinases. Amcasertib is undergoing multiple Phase I and Phase II studies as monotherapy and combination therapy for treating a range of tumor types.